Accelerating development of genetic therapies for muscular dystrophies
The aim of MAGIC is to accelerate the development of gene therapies and genome editing strategies for muscular dystrophies by creating advanced humanized muscle models and innovative gene therapy approaches, ultimately improving the lives of individuals affected by these debilitating diseases.
Key Objectives
- Creating accurate humanized muscle models.
- Developing precise gene therapies and genome editing strategies.
- Engineering disease-specific muscle-on-chip devices.
- Assessing safety and efficacy of novel gene therapies.
- Exploring gene editing strategies for neuromuscular disorders.
- Facilitating translation and exploitation of project outputs.
- Ensuring patient perspectives remain central to the research.
See how MAGIC is working to reach these key objectives
Latest News
Meet BIOND Solutions in the MAGIC Project Consortium
We ask MAGIC partners why they are joining this project. This time, we are speaking with Dr Kate Adcock, Director of Research and Innovation, Muscular Dystrophy UK.
Meet Duchenne Data Foundation in the MAGIC Project Consortium
We ask MAGIC partners why they are joining this project. This time, we are speaking with Dr Kate Adcock, Director of Research and Innovation, Muscular Dystrophy UK.
Meet Muscular Dystrophy UK in the MAGIC Project Consortium
We ask MAGIC partners why they are joining this project. This time, we are speaking with Dr Kate Adcock, Director of Research and Innovation, Muscular Dystrophy UK.